Premarket Approval application for Lumicell™ Direct Visualization System also accepted by FDA LUMISIGHT and the Lumicell DVS would be the first and only optical imaging agent and device solution to ...
As many as 40% of lumpectomies leave positive margins that necessitate a second surgery, but a novel fluorescent imaging agent used along with a direct visualization system may improve complete ...
Permanent HCPCS code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™, with commercial ...
Hunterdon Medical Center and The Institute for Advanced Reconstruction proudly announce being the first healthcare providers on the East Coast to use the Lumicell® Direct Visualization System for ...
Lumicell Inc. sees a brighter future now that it has secured U.S. FDA approval for both its new drug application for Lumisight (pegulicianine) optical imaging agent and premarket approval for the ...
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is thrilled to announce its upcoming ...
NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results